Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcutis Biotherapeutics Inc ARQT

Healthcare Biotechnology
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment... see more

Recent & Breaking News (NDAQ:ARQT)

Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

GlobeNewswire August 23, 2022

Arcutis Announces Arcutis Cares(TM) Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients

GlobeNewswire August 22, 2022

Arcutis Launches ZORYVE(TM) (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older

GlobeNewswire August 10, 2022

Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 4, 2022

Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

GlobeNewswire August 4, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 3, 2022

Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire August 2, 2022

Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire August 2, 2022

Arcutis to Host Investor Conference Call Today to Discuss the FDA Approval of ZORYVE(TM) (roflumilast) Cream 0.3% for Plaque Psoriasis

GlobeNewswire August 1, 2022

FDA Approves Arcutis' ZORYVE(TM) (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

GlobeNewswire July 29, 2022

Arcutis Biotherapeutics Reaches Regulatory Milestone with Health Canada Acceptance of New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

Canada NewsWire July 11, 2022

Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

GlobeNewswire July 11, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 5, 2022

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

GlobeNewswire June 6, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 3, 2022

CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

GlobeNewswire May 25, 2022

Nationwide Survey of People with Seborrehic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

GlobeNewswire May 25, 2022

Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 5, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 5, 2022

Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis

GlobeNewswire April 6, 2022